- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about GILD
Recent news which mentions GILD
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
February 17, 2022
From Benzinga
Hookipa Pharma Stock Surges On HIV Pact With Gilead
February 16, 2022
From Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
February 16, 2022
From Benzinga
Inside Gilead's Lackluster $7.2 Billion Q4 Earnings
February 16, 2022
From Motley Fool
3 Biotech Stocks to Buy in February
February 16, 2022
From Motley Fool
Tracking Gilead's 4 Big Stories and a Lawsuit in 2022
February 15, 2022
From Motley Fool
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
From Benzinga
Is the FDA's Partial Hold Bad News for Gilead Investors?
February 12, 2022
From Motley Fool
If You Invested $100 In This Stock 20 Years Ago, Here's How Much You Would Have Today
February 11, 2022
Tickers
GILD
From Benzinga
Gilead's Remdesivir Retains Antiviral Activity Against Several COVID-19 Variants, Including Omicron
February 11, 2022
Tickers
GILD
From Benzinga
2 Green Flags For Gilead Sciences' Future
February 11, 2022
From Motley Fool
Biden says it’s ‘probably premature’ for states to drop face mask requirements as Nevada and its casinos become latest to do so
February 11, 2022
From MarketWatch
2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows
February 10, 2022
From Motley Fool
The 7 Highest Dividend Stocks for Income Investors
February 09, 2022
From InvestorPlace
Glaxo's Q4 Pharma Sales Jump 20% Boosted By COVID-19 Treatment; Prepares For Spin-Off
February 09, 2022
From Benzinga
RedHill Biopharma's COVID-19 Antiviral Cuts Mortality By 70% In Remdesivir Treated Patients
February 07, 2022
From Benzinga
‘You will not believe what I’ve just found.’ Inside the ivermectin saga: a hacked password, mysterious websites and faulty data
February 07, 2022
From MarketWatch
Why Jim Cramer Believes Loves Berkshire Hathaway And Rivian
February 07, 2022
From Benzinga
3 Biotech Stocks That Could Make You Richer in February (and Beyond)
February 05, 2022
From Motley Fool
5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet
February 04, 2022
From InvestorPlace
COVID-19 treatments raked in billions of dollars in 2021. How will they do this year?
February 04, 2022
From MarketWatch
How Big Are Gilead's Latest COVID Wins?
February 03, 2022
From Motley Fool
From Benzinga
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
February 02, 2022
From Benzinga
Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates
February 02, 2022
Tickers
GILD
From Benzinga
Gilead Sciences (GILD) Q4 2021 Earnings Call Transcript
February 02, 2022
Tickers
GILD
From Motley Fool
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 01, 2022
From Benzinga
Gilead earnings slammed by legal settlement, stock falls
February 01, 2022
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.